Praxis Precision Medicines, Inc.
PRAX
Kedudukan dalam Saham
#2616
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Harga Saham
$260.52
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$7.27B
Perubahan (1 hari)
7.76%
Perubahan (1 tahun)
48.81%
Negara
US
Perdagangan Praxis Precision Medicines, Inc. (PRAX)
Kategori
Healthcare
Pendapatan untuk Praxis Precision Medicines, Inc. (PRAX)
Pendapatan pada Jun 2026 TTM: $-339.13M
Menurut laporan kewangan terkini Praxis Precision Medicines, Inc., pendapatan semasa syarikat ialah $-339.13M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-123.28M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-214.03M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Praxis Precision Medicines, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-339.13M | 85.50% |
| 2024 | $-182.82M | 48.30% |
| 2023 | $-123.28M | -42.40% |
| 2022 | $-214.03M | 28.11% |
| 2021 | $-167.06M | 170.20% |
| 2020 | $-61.83M | 73.69% |
| 2019 | $-35.60M | 34.82% |
| 2018 | $-26.40M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,655.44% |
US
|
|
| $-3.09B | 810.28% |
US
|
|
| $-4.02B | 1,084.28% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -675.20% |
NL
|
